已发表论文

Anti-amyloid aggregation activity of novel carotenoids: implications for Alzheimer’s drug discovery

 

Authors Lakey-Beitia J, Doens D, Jagadeesh Kumar D, Murillo E, Fernández PL, Rao KS, Durant-Archibold AA

Received 14 February 2017

Accepted for publication 7 April 2017

Published 15 May 2017 Volume 2017:12 Pages 815—822

DOI https://doi.org/10.2147/CIA.S134605

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 6

Editor who approved publication: Dr Richard Walker

Abstract: Alzheimer’s disease (AD) is the leading cause of dementia, affecting approximately 33.5 million people worldwide. Aging is the main risk factor associated with AD. Drug discovery based on nutraceutical molecules for prevention and treatment of AD is a growing topic. In this sense, carotenoids are phytochemicals present mainly in fruits and vegetables with reported benefits for human health. In this research, the anti-amyloidogenic activity of three carotenoids, cryptocapsin, cryptocapsin-5,6-epoxide, and zeaxanthin, was assessed. Cryptocapsin showed the highest bioactivity, while cryptocapsin-5,6-epoxide and zeaxanthin exhibited similar activity on anti-aggregation assays. Molecular modeling analysis revealed that the evaluated carotenoids might follow two mechanisms for inhibiting Aβ aggregation: by preventing the formation of the fibril and through disruption of the Aβ aggregates. Our studies provided evidence that cryptocapsin, cryptocapsin-5,6-epoxide, and zeaxanthin have anti-amyloidogenic potential and could be used for prevention and treatment of AD.
Keywords: Alzheimer’s disease, aging, anti-amyloidogenic activity, cryptocapsin, cryptocapsin-5,6-epoxide, zeaxanthin